WO2002083097A3 - Drug delivery system for hydrophobic drugs - Google Patents

Drug delivery system for hydrophobic drugs Download PDF

Info

Publication number
WO2002083097A3
WO2002083097A3 PCT/CA2002/000508 CA0200508W WO02083097A3 WO 2002083097 A3 WO2002083097 A3 WO 2002083097A3 CA 0200508 W CA0200508 W CA 0200508W WO 02083097 A3 WO02083097 A3 WO 02083097A3
Authority
WO
WIPO (PCT)
Prior art keywords
production
hydrophobic drugs
delivery system
drug delivery
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2002/000508
Other languages
French (fr)
Other versions
WO2002083097A2 (en
Inventor
Ronald E Boch
Dev Mitra Ranji Singh
Iman Karmadi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novelion Therapeutics Inc
Original Assignee
QLT Inc
Quadra Logic Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by QLT Inc, Quadra Logic Technologies Inc filed Critical QLT Inc
Priority to CA002439500A priority Critical patent/CA2439500C/en
Priority to JP2002580901A priority patent/JP4194847B2/en
Priority to HK04103136.5A priority patent/HK1060285B/en
Priority to DE60229366T priority patent/DE60229366D1/de
Priority to NZ527922A priority patent/NZ527922A/en
Priority to EP02721896A priority patent/EP1377274B1/en
Publication of WO2002083097A2 publication Critical patent/WO2002083097A2/en
Publication of WO2002083097A3 publication Critical patent/WO2002083097A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

Compositions comprising microaggregates containing hydrophobic drugs, as well as methods for their production, are described. Suchmicroaggregates may include micelle structures or combinations thereof with liposomes, and constitute an effective delivery vehicle for a hydrophobic agent. Methods for microaggregate production include the use of preferred lipid compounds and processing conditions favoring the production of small aggregates for improved filter sterilization.
PCT/CA2002/000508 2001-04-11 2002-04-10 Drug delivery system for hydrophobic drugs Ceased WO2002083097A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002439500A CA2439500C (en) 2001-04-11 2002-04-10 Drug delivery system for hydrophobic drugs
JP2002580901A JP4194847B2 (en) 2001-04-11 2002-04-10 Drug delivery system for hydrophobic drugs
HK04103136.5A HK1060285B (en) 2001-04-11 2002-04-10 Drug delivery system for photosensitizers
DE60229366T DE60229366D1 (en) 2001-04-11 2002-04-10
NZ527922A NZ527922A (en) 2001-04-11 2002-04-10 Compositions comprising microaggregates of photosensitizers and phospholipids
EP02721896A EP1377274B1 (en) 2001-04-11 2002-04-10 Drug delivery system for photosensitizers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/833,406 2001-04-11
US09/833,406 US6984395B2 (en) 2001-04-11 2001-04-11 Drug delivery system for hydrophobic drugs

Publications (2)

Publication Number Publication Date
WO2002083097A2 WO2002083097A2 (en) 2002-10-24
WO2002083097A3 true WO2002083097A3 (en) 2003-03-13

Family

ID=25264324

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/000508 Ceased WO2002083097A2 (en) 2001-04-11 2002-04-10 Drug delivery system for hydrophobic drugs

Country Status (11)

Country Link
US (3) US6984395B2 (en)
EP (2) EP1900357A3 (en)
JP (3) JP4194847B2 (en)
AT (1) ATE411004T1 (en)
CA (1) CA2439500C (en)
DE (1) DE60229366D1 (en)
ES (1) ES2315359T3 (en)
NZ (1) NZ527922A (en)
RU (1) RU2279872C2 (en)
WO (1) WO2002083097A2 (en)
ZA (1) ZA200306728B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9284512B2 (en) 2009-10-12 2016-03-15 Elevance Renewable Sicences, Inc. Methods of refining and producing dibasic esters and acids from natural oil feedstocks

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
CA2466103C (en) * 2001-11-02 2010-06-15 The Governors Of The University Of Alberta Micelle compositions containing pegylated phospholipids and a photosensitizer
TW200307563A (en) * 2002-02-14 2003-12-16 Sixty Inc C Use of BUCKYSOME or carbon nanotube for drug delivery
DE60335469D1 (en) 2002-07-02 2011-02-03 Univ Texas RADIOACTIVELY MARKED COMPOUNDS AND LIPOSOME AND THEIR MANUFACTURING AND APPLICATION METHOD
EP1581187A2 (en) * 2002-12-06 2005-10-05 Board Of Regents The University Of Texas System Compositions and methods related to lipid:emodin formulations
EP1631496B1 (en) 2003-04-28 2014-02-26 Medical Instill Technologies, Inc. Container with valve assembly for filling and dispensing substances, and apparatus and method for filling
US11324698B2 (en) 2003-08-28 2022-05-10 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
US20070003607A1 (en) * 2003-09-02 2007-01-04 Vibhudutta Awasthi Neutral liposome-encapsulated compounds and methods of making and using thereof
NZ589967A (en) * 2004-01-14 2012-07-27 Gilead Sciences Inc Lipid-based dispersions useful for drug delivery
CA2457214A1 (en) * 2004-02-06 2005-08-06 Qlt Inc. Photodynamic therapy for the treatment of acne
EP1755676B1 (en) * 2004-06-09 2012-11-28 QLT, Inc. Photodynamic therapy for the treatment of hyperactive sebaceous gland disorders using topically applied verteporfin and/or lemuteporfin
CN1840193B (en) * 2005-03-29 2010-05-12 中国科学院生物物理研究所 Nanomicelle formulation of anthracycline antitumor antibiotics entrapped in PEGylated phospholipids
US20070031482A1 (en) * 2005-08-02 2007-02-08 Ceramoptec Industries, Ind. PDT treatment method for cellulites and cosmetic use
ES2275443B1 (en) * 2005-11-30 2008-06-01 Italfarmaco, S.A. LIPOSOMAS PREPARATION PROCEDURE.
US20070154403A1 (en) * 2006-01-05 2007-07-05 Thomas Skold Oral, Pulmonary and Transmucosal Delivery Composition
WO2007127286A2 (en) * 2006-04-24 2007-11-08 Medical Instill Technologies, Inc. Needle penetrable and laser resealable lyophilization device and related method
JP2009536215A (en) * 2006-05-02 2009-10-08 ユニバーシティ オブ マイアミ Topical coenzyme Q10 formulation and treatment of pain, fatigue, and wounds
US8858989B2 (en) * 2006-05-18 2014-10-14 Biolitec Pharma Marketing Ltd Gel-formulations of hydrophobic photosensitizers for mucosal applications
US8211051B2 (en) * 2006-09-24 2012-07-03 Delaporte Stephen E Electroactive polymer actuated cerebrospinal fluid shunt
CZ2006743A3 (en) * 2006-11-28 2008-03-26 Fyziologický ústav AV CR Liposomal Gel Phthalocyanine Formulation for Photodynamic Therapy of Tumors and its Preparation
WO2008088037A1 (en) * 2007-01-18 2008-07-24 National University Corporation Chiba University Finely particulate medicinal preparation
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
RU2367434C1 (en) * 2008-04-22 2009-09-20 Виктор Александрович Борисов Photosensitiser and method for preparing thereof
US20110257253A1 (en) * 2008-12-26 2011-10-20 Samyang Corporation Preparation method of polymeric micellar nanoparticles composition containing a poorly water-soluble drug
US8709473B1 (en) * 2009-01-28 2014-04-29 Abbott Cardiovascular Systems Inc. Method of targeting hydrophobic drugs to vascular lesions
US20100233224A1 (en) * 2009-02-23 2010-09-16 Epir Technologies, Inc. Photolytic release of biocides for high efficiency decontamination through phospholipid nanoparticles
US8815931B2 (en) * 2009-04-28 2014-08-26 Biolitec Pharma Marketing Ltd Oral formulations for tetrapyrrole derivatives
RU2012125350A (en) * 2009-11-20 2013-12-27 Клавис Фарма Аса Parenteral preparations of gemcitabine derivatives
WO2011091160A1 (en) * 2010-01-20 2011-07-28 Henry Wu Custom-formulated phospholipid microbubbles and methods and uses thereof
JP2012184199A (en) * 2011-03-07 2012-09-27 Nara Institute Of Science & Technology Water-soluble photosensitizing material using fullerene derivative
CN102302450B (en) * 2011-09-06 2013-02-27 复旦大学 Hydrophobic drug-albumin-dextran nanoemulsion and its preparation method and application
PT2768484T (en) * 2011-10-21 2019-10-28 Jazz Pharmaceuticals Res Llc LYOPHILIZED LIPOSOMES
CN104684546A (en) * 2012-06-07 2015-06-03 哈佛大学校长及研究员协会 Nanotherapeutics for drug targeting
JP6112498B2 (en) * 2012-07-20 2017-04-12 株式会社 Ｍ Ｌａｂｓ Preservative / surfactant-free cosmetic raw material liquid, preparation method for cosmetics and cosmetic raw material liquid
WO2014100379A1 (en) * 2012-12-19 2014-06-26 The Research Foundation For The State University Of New York Compositions and method for light triggered release of materials from nanovesicles
KR102310786B1 (en) 2013-02-01 2021-10-12 존원 파마, 인코포레이티드 Remote loading of sparingly water-soluble drugs into liposomes
GB201318787D0 (en) * 2013-10-24 2013-12-11 Univ Leiden Upconverting vehicles and uses
CN106999419A (en) 2014-08-04 2017-08-01 佐尼奥尼制药股份有限公司 Remote loading sparingly water-soluble medicine is to lipid film bubble
JP6036879B2 (en) * 2015-03-04 2016-11-30 栗田工業株式会社 Selective permeable membrane for water treatment and method for producing the same
WO2016161428A1 (en) * 2015-04-02 2016-10-06 The Research Foundation For The State University Of New York Serum-stable compositions and methods for light-triggered release of materials
CN108289845A (en) 2015-09-14 2018-07-17 维吉思康科技公司 Subcutaneously, sublingual and oral medication spatial stability carrier, composition and method for treating mammal
CA3063916A1 (en) 2017-05-17 2018-11-22 Berg Llc Use of coenzyme q10 formulations in the treatment and prevention of epidermolysis bullosa
RU2674025C1 (en) * 2017-10-25 2018-12-04 Общество с ограниченной ответственностью "Научно-производственная фирма "ЭЛЕСТ" (ООО "НПФ "ЭЛЕСТ") Drug based on porphyrinic photosensitizer of coproporphyrin for treatment of skin cancer by photodynamic therapy method
WO2019173884A1 (en) * 2018-03-15 2019-09-19 Bebeachibuli Romeo Biological normalizer, process for producing a biological normalizer and products produced with the biological normalizer
US10716758B2 (en) * 2018-04-09 2020-07-21 Southwest Research Institute Liposomal statin formulation
EA038105B1 (en) * 2018-06-13 2021-07-07 Тютор С.А.С.И.Ф.И.А. Method of producing a pharmaceutical composition comprising bortezomib, product of the method
CN111569074B (en) * 2020-06-18 2021-05-04 吉林大学 Nanosheet with both selectivity and photothermal antibacterial properties, preparation method and application thereof
AU2022270670A1 (en) 2021-05-05 2023-11-30 Nejat Duzgunes Liposome-encapsulated corticosteriods inhibit sars-cov-2 replication and reduces lung inflammation
CN119326732B (en) * 2024-10-25 2025-08-05 福建医科大学附属协和医院 Ternary nanometer self-assembled particles that respond to and regulate arterial thrombosis microenvironment and preparation method thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5257970A (en) * 1992-04-09 1993-11-02 Health Research, Inc. In situ photodynamic therapy
WO1997004746A1 (en) * 1995-08-02 1997-02-13 Qlt Phototherapeutics, Inc. Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizers
WO1998048621A1 (en) * 1997-04-29 1998-11-05 New York Blood Center, Inc. Methods for viral inactivation and compositions for use in same
US5929105A (en) * 1997-05-07 1999-07-27 Qltphoto Therapeutics, Inc. Ethylene glycol esters as photoactive agents
US6074666A (en) * 1992-02-05 2000-06-13 Qlt Phototherapeutics, Inc. Liposome compositions of porphyrin photosensitizers
WO2000034763A2 (en) * 1998-12-11 2000-06-15 The University Of British Columbia Separation of photosensitizer isomers and stereoisomers by laser-induced fluorescence capillary electrophoresis
WO2001085213A2 (en) * 2000-05-08 2001-11-15 The University Of British Columbia Supports for photosensitizer formulations

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5435989A (en) * 1982-03-30 1995-07-25 Vestar, Inc. Method of targeting a specific location in a body
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US4577636A (en) * 1982-11-23 1986-03-25 The Beth Israel Hospital Association Method for diagnosis of atherosclerosis
US4512762A (en) * 1982-11-23 1985-04-23 The Beth Israel Hospital Association Method of treatment of atherosclerosis and a balloon catheter for same
US4753788A (en) * 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
US4753958A (en) * 1985-02-07 1988-06-28 University Of Cal Photochemotherapy of epithelial diseases with derivatives of hematoporphyrins
US4776991A (en) * 1986-08-29 1988-10-11 The United States Of America As Represented By The Secretary Of The Navy Scaled-up production of liposome-encapsulated hemoglobin
JPS63130537A (en) * 1986-11-19 1988-06-02 Ichimaru Pharcos Co Ltd Skin agent containing placenta derived preformed chemical mediator
US5320906A (en) * 1986-12-15 1994-06-14 Vestar, Inc. Delivery vehicles with amphiphile-associated active ingredient
US5171749A (en) * 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US4883790A (en) * 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents
US4920143A (en) * 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US4946683A (en) * 1987-11-18 1990-08-07 Vestar, Inc. Multiple step entrapment/loading procedure for preparing lipophilic drug-containing liposomes
US5096629A (en) * 1988-08-29 1992-03-17 501 Nippon Fine Chemical Co., Ltd. Method for preparing lipid powder for use in preparing liposomes and method for preparing liposomes
US5010073A (en) * 1989-10-05 1991-04-23 The Rockefeller University Use of liposomes as carriers for metalloporphyrins
US5270053A (en) * 1990-04-03 1993-12-14 Ciba-Geigy Corp. Parenterally administerable liposome formulation comprising synthetic lipid
CA2047969A1 (en) * 1990-08-17 1992-02-18 Thomas D. Madden Benzoporphyrin vesicles
US5095629A (en) * 1991-01-31 1992-03-17 Spectra-Physics Laserplane, Inc. Laser beam target
JPH06507904A (en) * 1991-05-23 1994-09-08 イマアーレクス・フアーマシユーチカル・コーポレーシヨン Oil-soluble compounds for magnetic resonance imaging
US6733776B1 (en) * 1992-04-02 2004-05-11 Anticancer, Inc. Method for promoting hair growth
US5329029A (en) * 1992-11-05 1994-07-12 Wan Barbara Y Phosphatidylalkanolamine derivatives and their use in generating phospholipid conjugates
AU677826B2 (en) * 1993-02-26 1997-05-08 Fountain Pharmaceuticals, Inc. Vaccine delivery system and shelf-stable precursor solution for remote encapsulation of active ingredients
JP2950520B2 (en) * 1993-04-02 1999-09-20 アンティキャンサー インコーポレーテド Methods for delivering beneficial formulations to hair follicles
FR2715566B1 (en) * 1994-02-03 1996-03-08 Synthelabo Concentrated aqueous solutions of argatroban.
FR2715846A1 (en) * 1994-02-07 1995-08-11 Rhone Poulenc Rorer Sa Injectable taxoid compsns. for treatment of tumours
US5833948A (en) * 1995-06-15 1998-11-10 Bracco Research S.A. Blood-pool imaging composition comprising micelles containing a lipophilic chelating agent and a non-ionic surfactant
US5885557A (en) * 1996-02-08 1999-03-23 Estee Lauder Inc. Compositions useful in the phototherapeutic treatment of proliferative skin disorders
US6375930B2 (en) * 1996-06-04 2002-04-23 Board Of Regents, The University Of Texas System Membrane incorporation of texaphyrins
RU2186562C2 (en) * 1996-08-22 2002-08-10 Ресеч Трайангл Фармасьютикалс Лтд. Composites presenting water-insoluble substance microparticles and method of their producing
HU224176B1 (en) * 1997-05-07 2005-06-28 The University Of British Columbia The benzoporphyrin derivative is a new class of photoactive compounds
US5880145A (en) * 1997-05-07 1999-03-09 The University Of British Columbia Class of benzoporphyrin derivative photoactive compounds
DE19838636A1 (en) * 1998-08-26 2000-03-02 Basf Ag Carotenoid formulations containing a mixture of beta-carotene, lycopene and lutein
US6696081B2 (en) * 2000-06-09 2004-02-24 Duke University Carbohydrate based lipid compositions and supramolecular structures comprising same
KR100392501B1 (en) * 2000-06-28 2003-07-22 동국제약 주식회사 Preparation Method for Sustained Release Microparticles by Multiple Emulsion Method and Micropartic les Thereof
US6984395B2 (en) 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
KR20040063901A (en) 2001-09-28 2004-07-14 에스페리온 테라피유틱스 인코포레이티드 Methods and apparatus for extrusion of vesicles at high pressure

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074666A (en) * 1992-02-05 2000-06-13 Qlt Phototherapeutics, Inc. Liposome compositions of porphyrin photosensitizers
US5257970A (en) * 1992-04-09 1993-11-02 Health Research, Inc. In situ photodynamic therapy
WO1997004746A1 (en) * 1995-08-02 1997-02-13 Qlt Phototherapeutics, Inc. Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizers
WO1998048621A1 (en) * 1997-04-29 1998-11-05 New York Blood Center, Inc. Methods for viral inactivation and compositions for use in same
US5929105A (en) * 1997-05-07 1999-07-27 Qltphoto Therapeutics, Inc. Ethylene glycol esters as photoactive agents
WO2000034763A2 (en) * 1998-12-11 2000-06-15 The University Of British Columbia Separation of photosensitizer isomers and stereoisomers by laser-induced fluorescence capillary electrophoresis
WO2001085213A2 (en) * 2000-05-08 2001-11-15 The University Of British Columbia Supports for photosensitizer formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TATMAN D ET AL: "Carotenohematoporphyrins as tumor -imaging dyes. Synthesis and in vitro photophysical characterization", PHOTOCHEMISTRY AND PHOTOBIOLOGY, OXFORD, GB, vol. 68, no. 4, October 1998 (1998-10-01), pages 459 - 466, XP002114439, ISSN: 0031-8655 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9284512B2 (en) 2009-10-12 2016-03-15 Elevance Renewable Sicences, Inc. Methods of refining and producing dibasic esters and acids from natural oil feedstocks

Also Published As

Publication number Publication date
JP5154296B2 (en) 2013-02-27
EP1900357A2 (en) 2008-03-19
JP2008201807A (en) 2008-09-04
EP1377274A2 (en) 2004-01-07
RU2279872C2 (en) 2006-07-20
ATE411004T1 (en) 2008-10-15
US8852629B2 (en) 2014-10-07
CA2439500A1 (en) 2002-10-24
CA2439500C (en) 2008-11-18
EP1900357A3 (en) 2009-05-20
ZA200306728B (en) 2004-09-17
NZ527922A (en) 2005-09-30
US20020156062A1 (en) 2002-10-24
HK1060285A1 (en) 2004-08-06
WO2002083097A2 (en) 2002-10-24
US6984395B2 (en) 2006-01-10
JP2012224634A (en) 2012-11-15
JP2004532219A (en) 2004-10-21
US20100247447A1 (en) 2010-09-30
DE60229366D1 (en) 2008-11-27
ES2315359T3 (en) 2009-04-01
EP1377274B1 (en) 2008-10-15
RU2003132694A (en) 2005-03-10
JP4194847B2 (en) 2008-12-10
US20060039965A1 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
EP1900357A3 (en) Drug delivery system for hydrophobic drugs
WO2005055945A3 (en) Mucoadhesive drug delivery devices and methods of making and using thereof
WO2004082628A3 (en) Improved bioavailability and improved delivery of acidic pharmaceutical drugs
WO2004026231A3 (en) Formulation for lipophilic agents
WO2009064964A3 (en) Switchable nano-vehicle delivery systems, and methods for making and using them
WO2002013873A3 (en) P97-active agent conjugates and their methods of use
WO2001095899A8 (en) Pharmaceutical compositions comprising cannabidiol derivatives
DK1392254T3 (en) Micelle drug delivery system for hydrophobic drugs
WO2001019406A3 (en) Amphiphilic prodrugs
WO2003028657A3 (en) Compositions for oral gene therapy and methods of using same
WO2005063201A3 (en) Liposomes and liposomal compositions for vaccination and drug delivery
AU2002323151A1 (en) Application of lipid vehicles and use for drug delivery
WO2004093795A3 (en) Compositions for delivery of drug combinations
AU5154000A (en) Stabilization and acoustic activation of polymeric micelles for drug delivery
WO2003043586A3 (en) Compositions for sustained action product delivery
WO2003045306A3 (en) Phenoxy amine compounds and compositions for delivering active agents
DE60210552D1 (en) Process for the preparation of a solid pharmaceutical preparation containing a sparingly soluble active substance
WO2003028696A8 (en) Compositions for delivery of drug combinations
WO2000003753A3 (en) Microdisperse drug delivery systems
AU2002213698A1 (en) Needleless syringe for the subcutaneous delivery of therapeutic agents
WO2001082897A3 (en) Liposome drug delivery
BR9812316A (en) Formulations of liposomal camptothecin
DE50313292D1 (en) Revealing liposomes and their use for the pulmonary application of drugs
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
WO2002015959A3 (en) Compounds and compositions for delivering active agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2439500

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003/06728

Country of ref document: ZA

Ref document number: 200306728

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 527922

Country of ref document: NZ

Ref document number: 2002252874

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002721896

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002580901

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002721896

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 527922

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 527922

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2002252874

Country of ref document: AU